Last 4,040 KRW
Change Today -5.00 / -0.12%
Volume 106.5K
009420 On Other Exchanges
Symbol
Exchange
Korea SE
As of 2:11 AM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

hanall biopharma co ltd (009420) Snapshot

Open
4,050
Previous Close
4,045
Day High
4,100
Day Low
3,980
52 Week High
09/25/13 - 7,090
52 Week Low
06/25/14 - 3,555
Market Cap
168.9B
Average Volume 10 Days
134.7K
EPS TTM
-529.00
Shares Outstanding
41.8M
EX-Date
12/29/09
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HANALL BIOPHARMA CO LTD (009420)

Related News

No related news articles were found.

hanall biopharma co ltd (009420) Related Businessweek News

No Related Businessweek News Found

hanall biopharma co ltd (009420) Details

HanAll BioPharma Co., Ltd., a biopharmaceutical company, researches and develops biopharmaceutical products worldwide. It develops H176 and HL177, a series of anti-cancer agents for cancer metabolism; and HL156FIB, an EMT inhibitor for fibrotic diseases, such as IPF, peritoneal fibrosis, hypertrophic scar, etc. The company also develops products for infectious diseases, such as HL143, a single amino acid variant of native IFN-alpha-2a; and Hanferon, a protease resistant for genotype 1 hepatitis C patients. In addition, it provides HL036, a TNF-alpha receptor fragment for the treatment of inflammatory diseases caused by TNF-alpha, such as uveitis, dry eyes, and AMD. Further, the company offers HL161, an anti-FcRn mAb for the treatment of autoimmune diseases caused by IgG auto antibodies and immune complex mediated glomerular diseases; and HL009, an adenosylcobalamin liposomal gel in the area of immunology diseases. Additionally, it provides Vitatropin, an oral human growth hormone, as well as HL-178, a negative regulator of TXNIP in the area of endocrinology diseases; and HL040, a combination of atorvastatin and losartan for the treatment of cardiovascular disease, such as hypertension and hyperlipidemia. The company also exports its products. HanAll BioPharma Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.

Founded in 1973

hanall biopharma co ltd (009420) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hanall biopharma co ltd (009420) Key Developments

HanAll Biopharma Co., Ltd.(KOSE:A009420) dropped from KOSPI 200 Index

HanAll Biopharma Co., Ltd. will be removed from the KOSPI 200 Index.

HanAll Biopharma Co., Ltd., Annual General Meeting, Mar 28, 2014

HanAll Biopharma Co., Ltd., Annual General Meeting, Mar 28, 2014., at 10:00 Korea Standard Time. Location: small, Songpa women's Hall 6th floor. Agenda: To consider financial statements for the year ended December 31, 2013; and to consider other issues.

HanAll Biopharma Co., Ltd. Presents at 8th Annual BIO Europe Spring 2014, Mar-11-2014 11:00 AM

HanAll Biopharma Co., Ltd. Presents at 8th Annual BIO Europe Spring 2014, Mar-11-2014 11:00 AM. Venue: OVAL Lingotto, Turin, Italy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
009420:KS 4,040.00 KRW -5.00

009420 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 009420.
View Industry Companies
 

Industry Analysis

009420

Industry Average

Valuation 009420 Industry Range
No financial data is available for 009420.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HANALL BIOPHARMA CO LTD, please visit www.hanallbiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.